Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Arcerix in Idiopathic Recurrent Pericarditis Extension Study
NCT05673902Phase 3Active, not recruiting
- Sponsor
- R-Pharm
- Start
- Dec 2020
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of goflikicept in idiopathic recurrent pericarditis (IRP), sponsored by R-Pharm. Started Dec 2020; status: active, not recruiting.
02
Drugs
goflikicept
03
Conditions
idiopathic recurrent pericarditis (IRP)
Beyond the preview
Go deeper on NCT05673902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673902.